Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is a high-performing company, with a strong focus on growth, a diverse range of products, and a solid financial outlook. The company's strong performance and growth potential are supported by increasing sales projections, a robust product pipeline, and a focus on expanding into international markets. Risks such as potential commercial and regulatory challenges should be carefully monitored, but overall, Edwards Lifesciences presents a positive investment opportunity for those seeking exposure to the medical device industry.

Bears say

Edwards Lifesciences is a global leader in advanced medical devices for structural heart diseases with significant exposure and strong sales outside of the US. However, with increasing competition and pricing pressure in key markets, coupled with limited growth potential in its core products, it is likely to face challenges in maintaining its current growth trajectory and profitability. As a result, the high valuation multiples may not be sustainable in the long-term, leading to a negative outlook for the stock.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.